ArticlePLOS global public health2026
Time to incidence of tuberculosis and its predictors among adult HIV/AIDS patients who initiated ART by the Universal Test and Treat approach in Silte Zone, Ethiopia, 2023.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a leading cause of morbidity and mortality among people living with HIV. TB/HIV co-infection continues to challenge global TB control efforts. This study aimed to estimate the incidence and identify predictors of TB among adult HIV-infected patients who initiated antiretroviral therapy (ART) under the Universal Test and Treat (UTT) approach in Silte Zone, Ethiopia. An institution-based retrospective cohort study was conducted among 404 adult HIV patients enrolled in ART. Participants were selected using simple random sampling. Data were extracted using a structured checklist via Kobo Toolbox and analyzed using STATA version 14. Cox proportional hazards regression models were applied to identify predictors of TB. Statistical significance was declared at p < 0.05 with 95% confidence intervals. The proportional hazards assumption was assessed using statistical tests and graphical methods. The median age was 36 years, with near-equal sex distribution. Most participants initiated ART at WHO clinical stages I-II. Approximately 70% had good adherence, and over 80% disclosed their HIV status. The predominant regimen was TDF-3TC-EFV. The overall TB incidence density rate was 5.33 per 1000 person-months (95% CI: 3.68-7.77). The incidence of new TB was 4.0 per 1000 person-months (95% CI: 2.60-6.13), while reinfection was 1.3 per 1000 person-months (95% CI: 0.63-2.70). TB-free survival probabilities at 6, 12, and 18 months were 0.99, 0.93, and 0.90, respectively. Male sex (AHR: 5.05), non-disclosure of HIV status (AHR: 6.29), underweight status (AHR: 3.07), CD4 count <200 cells/μL (AHR: 5.63), and poor ART adherence (AHR: 7.05) were significant predictors. Although TB incidence declined under the UTT approach, risk remained elevated during the first year of ART. Targeted interventions promoting early diagnosis, adherence support, nutritional care, and safe disclosure are essential to reduce TB burden among people living with HIV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.